JPMorgan Downgrades Ultragenyx Pharma (RARE) to Neutral

September 3, 2026 4:10 AM

JPMorgan analyst Anupam Rama downgraded Ultragenyx Pharma (NASDAQ: RARE) from Overweight to Neutral with a price target of $36.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found